Workshop report treating hepatitis C in HIV-infected patients: where are we now?
The 1st International Workshop on HIV and Hepatitis Coinfection was held in Noordwijk, the Netherlands, 2-4 December 2004. This report outlines issues raised at the workshop concerning the treatment of hepatitis C in HIV-coinfected patients. Clinical trials using pegylated interferon in combination with ribavirin have provided positive outcomes, although clinicians still face a number of challenges in learning how best to use these drugs.
Perronne
Christian
C
Centre Hospitalier Universitaire Raymond Poincare, Universite de Versailles, Garches, France. c.perronne@rpc.ap-hop-paris.fr
D000998:Antiviral Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005602:France; D015658:HIV Infections / Q000150:complications*; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D015337:Multicenter Studies as Topic; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D013030:Spain; D014481:United States
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a